Loading...

Hexima Limited

HXL.AXASX
Healthcare
Biotechnology
$0.01
$0.00(0.00%)
Australian Market is Open • 13:37

Hexima Limited (HXL.AX) Stock Competitors & Peer Comparison

See (HXL.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
HXL.AXA$0.01+0.00%542.9K-0.65-A$0.02+11.54%
CSL.AXA$96.22-1.07%46.9B11.50A$8.52+4.35%
TLX.AXA$14.26-3.97%5B-490.67-A$0.03N/A
MSB.AXA$2.04-0.49%2.7B-21.10-A$0.10N/A
NEU.AXA$12.35-3.89%1.6B55.61A$0.23N/A
CU6.AXA$2.60-9.72%1.1B-10.36-A$0.28N/A
PYC.AXA$1.33-7.96%833.8M-17.87-A$0.08N/A
OPT.AXA$0.60+0.00%820.8M-1.40-A$0.43N/A
RAC.AXA$2.61+2.76%516.4M-55.20-A$0.05N/A
CUV.AXA$9.13-4.30%477.4M14.80A$0.64+0.53%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

HXL.AX vs CSL.AX Comparison May 2026

HXL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HXL.AX stands at 542.9K. In comparison, CSL.AX has a market cap of 46.9B. Regarding current trading prices, HXL.AX is priced at A$0.01, while CSL.AX trades at A$96.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HXL.AX currently has a P/E ratio of -0.65, whereas CSL.AX's P/E ratio is 11.50. In terms of profitability, HXL.AX's ROE is -0.32%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, HXL.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for HXL.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions